Differences between bisphosphonates in binding affinities for hydroxyapatite

Journal of Biomedical Materials Research - Part B Applied Biomaterials

Volumn 92, Issue 1, 2010, Pages 149-155

  Lawson, M A ^a   Xia, Z ^a   Barnett, B L ^b   Triffitt, J T ^a   Phipps, R J ^c   Dunford, J E ^a   Locklin, R M ^a   Ebetino, F H ^c   Russell, R G G ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b UNIVERSITY OF CINCINNATI   (United States)

^c PROCTER AND GAMBLE PHARMACEUTICALS   (United States)

Author keywords

Bisphosphonates; Bone mineral; Hydroxyapatite binding; Risedronate; Zoledronate

Indexed keywords

BINDING AFFINITIES; BIOLOGICAL EFFECTS; BIOLOGICAL PROPERTIES; BISPHOSPHONATES; BONE DISEASE; BONE MINERAL; BONE MINERALS; BONE RESORPTION; CLINICAL STUDY; FAST PERFORMANCE LIQUID CHROMATOGRAPHIES; MINERAL BINDING; PHOSPHATE BUFFERS; RETENTION TIME; RISEDRONATE; SEM;

APATITE; BINDING ENERGY; BIOLOGICAL MATERIALS; BONE; CHROMATOGRAPHIC ANALYSIS; DISEASES; HAZARDOUS MATERIALS; HYDROXYAPATITE; LIQUID CHROMATOGRAPHY; MINERALS; SILICATE MINERALS;

BIOMATERIALS;

ADENOSINE DIPHOSPHATE; ADENOSINE TRIPHOSPHATE; ALENDRONIC ACID; BIOMATERIAL; BISPHOSPHONIC ACID DERIVATIVE; CARBOXYLIC ACID DERIVATIVE; CLODRONIC ACID; ETIDRONIC ACID; HYDROXYAPATITE; IBANDRONIC ACID; NE 10575; NE 10790; NE 58018; NE 58043; NE 58051; NE 58086; NE 97721; PAMIDRONIC ACID; PHOSPHATE; PHOSPHATE BUFFERED SALINE; RISEDRONIC ACID; UNCLASSIFIED DRUG; ZOLEDRONIC ACID;

ARTICLE; BINDING AFFINITY; DRUG BINDING; DRUG STRUCTURE; DRUG SYNTHESIS; FAST PROTEIN LIQUID CHROMATOGRAPHY; HUMAN; NONHUMAN; OSTEOLYSIS; PH;

BONE DENSITY CONSERVATION AGENTS; CHROMATOGRAPHY, LIQUID; DIPHOSPHONATES; DURAPATITE; ETIDRONIC ACID; IMIDAZOLES; SPECTROPHOTOMETRY, ULTRAVIOLET;

EID: 74749097970     PISSN: 15524973     EISSN: 15524981     Source Type: Journal    
DOI: 10.1002/jbm.b.31500     Document Type: Article

References (34)

1. Russell RG, Xia Z, Dunford JE, Oppermann U, Kwaasi A, Hulley PA, Kavanagh KL, Triffitt JT, Lundy MW, Phipps RJ, Barnett BL, Coxon FP, Rogers MJ, Watts NB, Ebetino FH. Bisphosphonates. An update on mechanisms of action and how these relate to clinical efficacy. Ann N Y Acad Sci 2007;1117:209-257.
2. Russell RGG, Watts NB, Ebetino FH, Rogers MJ. Mechanisms of action of bisphosphonates: Similarities and differences and their potential influence on clinical efficacy. Osteoporos Int 2008;19:733-759.
3. Fleisch H, Russell RG, Francis MD. Diphosphonates inhibit hydroxyapatite dissolution in vitro and bone resorption in tissue culture and in vivo. Science 1969;165:1262-1264.
4. Russell RG, Mühlbauer RC, Bisaz S, Williams DA, Fleisch H. The influence of pyrophosphate, condensed phosphates, phosphonates and other phosphate compounds on the dissolution of hydroxyapatite in vitro and on bone resorption induced by parathyroid hormone in tissue culture and in thyroparathyroidectomised rats. Calcif Tissue Res 1970;6:183-196.
5. Schenk R, Merz WA, Mühlbauer R, Russell RG, Fleisch H. Effect of ethane-1-hydroxy-1,1-diphosphonate (EHDP) and dichloromethylene diphosphonate (Cl 2 MDP) on the calcification and resorption of cartilage and bone in the tibial epiphysis and metaphysis of rats. Calcif Tissue Res 1973;11:196-214.
6. Fogelman I, Bessent RG, Turner JG, Citrin DL, Boyle IT, Greig WR. The use of whole-body retention of Tc-99m diphosphonate in the diagnosis of metabolic bone disease. J Nucl Med 1978;19:270-275.
7. Bevan JA, Tofe AJ, Benedict JJ, Francis MD, Barnett BL. Tc-99m HMDP (hydroxymethylene diphosphonate): A radiopharmaceutical for skeletal and acute myocardial infarct imaging. II. Comparison of Tc-99m hydroxymethylene diphosphonate (HMDP) with other technetium-labeled bone-maging agents in a canine model. J Nucl Med 1980:21;967-970.
8. Deutsch E, Barnett BL. Synthetic and structural aspects of technetium chemistry as related to nuclear medicine. In: Arthur E. Martell, editor. Inorganic Chemistry in Biology and Medicine. Washington, DC: American Chemistry Society; 1980. pp 103-119.
9. Black DM, Delmas PD, Eastell R, Reid IR, Boonen S, Cauley JA, Cosman F, Lakatos P, Leung PC, Man Z, Mautalen C, Mesenbrink P, Hu H, Caminis J, Tong K, Rosario-Jansen T, Krasnow J, Hue TF, Sellmeyer D, Eriksen EF, Cummings SR; HORIZON Pivotal Fracture Trial. Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med 2007;356: 1809-1822.
10. Reid IR, Brown JP, Burckhardt P, Horowitz Z, Richardson P, Trechsel U, Widmer A, Devogelaer JP, Kaufman JM, Jaeger P, Body JJ, Brandi ML, Broell J, Di Micco R, Genazzani AR, Felsenberg D, Happ J, Hooper MJ, Ittner J, Leb G, Mallmin H, Murray T, Ortolani S, Rubinacci A, Saaf M, Samsioe G, Verbruggen L, Meunier PJ. Intravenous zoledronic acid in postmenopausal women with low bone mineral density. N Engl J Med 2002;346:653-661.
11. Dunford JE, Thompson K, Coxon FP, Luckman SP, Hahn FM, Poulter CD, Ebetino FH, Rogers MJ. Structure-activity relationships for inhibition of farnesyl diphosphate synthase in vitro and inhibition of bone resorption in vivo by nitrogen-containing bisphosphonates. J Pharmacol Exp Ther 2001;296:235-242.
12. Francis MD, Russell RG, Fleisch H. Diphosphonates inhibit formation of calcium phosphate crystals in vitro and pathological calcification in vivo. Science 1969;165:1264-1266.
13. Fleisch HA, Russell RG, Bisaz S, Mühlbauer RC, Williams DA. The inhibitory effect of phosphonates on the formation of calcium phosphate crystals in vitro and on aortic and kidney calcification in vivo. Eur J Clin Invest 1970;1:12-18.
14. Nancollas GH, Tang R, Phipps RJ, Henneman Z, Gulde S, Wu W, Mangood A, Russell RG, Ebetino FH. Novel insights into actions of bisphosphonates on bone: Differences in interactions with hydroxyapatite. Bone 2006;38:617-627.
15. Ebrahimpour A, Francis MD. Bisphosphonate therapy in acute and chronic bone boss: Physical chemical considerations in bisphosphonate-related therapies. In: Bijvoet OLM, Fleisch HA, Canfield RE, Russell RGG, editors. Bisphosphonate on Bones. Amsterdam: Elsevier Publishing; 1995. pp 125-136.
16. Leu CT, Luegmayr E, Freedman LP, Rodan GA, Reszka AA. Relative binding affinities of bisphosphonates for human bone and relationship to antiresorptive efficacy. Bone 2006;38:628-636.
17. Papapoulos SE. Bisphosphonate actions: Physical chemistry revisited. Bone 2006;38:613-616. 18. Nakamura Y, Hayashi K, Abu-Ali S, Naito M, Fotovati A. Effect of preoperative combined treatment with alendronate and calcitriol on fixation of hydroxyapatite-coated implants in ovariectomized rats. J Bone Joint Surg Am 2008;90:824-832.
18. Little DG, McDonald M, Bransford R, Godfrey CB, Amanat N. Manipulation of the anabolic and catabolic responses with OP-1 and zoledronic acid in a rat critical defect model. J Bone Miner Res 2005;20:2044-2052.
19. Kurth AH, Eberhardt C, Müller S, Steinacker M, Schwarz M, Bauss F. The bisphosphonate ibandronate improves implant integration in osteopenic ovariectomized rats. Bone 2005; 37:204-210.
20. Wilkinson JM, Eagleton AC, Stockley I, Peel NF, Hamer AJ, Eastell R. Effect of pamidronate on bone turnover and implant migration after total hip arthroplasty: A randomized trial. J Orthop Res 2005;23:1-8.
21. Bobyn JD, Hacking SA, Krygier JJ, Harvey EJ, Little DG, Tanzer M. Zoledronic acid causes enhancement of bone growth into porous implants. J Bone Joint Surg Br 2005; 87:416-420.
22. Little DG, Peat RA, McEvoy A, Williams PR, Smith EJ, Baldock PA. Zoledronic acid treatment results in retention of femoral head structure after traumatic osteonecrosis in young Wistar rats. J Bone Miner Res 2003;18:2016-2022.
23. Lai KA, Shen WJ, Yang CY, Shao CJ, Hsu JT, Lin RM. The use of alendronate to prevent early collapse of the femoral head in patients with nontraumatic osteonecrosis. A randomized clinical study. J Bone Joint Surg Am 2005;87:2155-2159.
24. Josse S, Faucheux C, Soueidan A, Grimandi G, Massiot D, Alonso B, Janvier P, Laïb S, Pilet P, Gauthier O, Daculsi G, Guicheux JJ, Bujoli B, Bouler JM. Novel biomaterials for bisphosphonate delivery. Biomaterials 2005;26:2073-2080.
25. Roussière H, Montavon G, Laï S, Janvier P, Alonso B, Fayon F, Petit M, Massiot D, Bouler JM, Bujoli B. Hybrid materials applied to biotechnologies: Coating of calcium phosphates for the design of implants active against bone resorption disorders. J Mater Chem 2005;15:3869-3875.
26. Ebetino FH, Dansereau SM. Bisphosphonate antiresorptive structure activity relationships. In: Bijvoet OLM, Fleisch HA, Canfield RE, Russell RGG, editors. Bisphosphonate on Bones. New York: Elsevier Science Publishing; 1995. pp 139-153.
27. Sparidans RW, den Hartigh J. Chromatographic analysis of bisphosphonates. Pharm World Sci 1999;21:1-10.
28. van Beek ER, Löwik CW, Ebetino FH, Papapoulos SE. Binding and antiresorptive properties of heterocycle-containing bisphosphonate analogs: Structure-activity relationships. Bone 1998;23:437-442.
29. Ebetino FH, Emmerling P, Barnett B, Nancollas GH. Differentiation of hydroxyapatite affinity of bisphosphonate analogs for mechanism of action studies [abstract]. J Bone Miner Res 2004;19:S157.
30. Mukherjee S, Song Y, Oldfield E. NMR investigations of the static and dynamic structures of bisphosphonates on human bone: A molecular model. J Am Chem Soc 2008;130:1264-1273.
31. Henneman ZJ, Nancollas GH, Ebetino FH, Russell RG, Phipps RJ. Bisphosphonate binding affinity as assessed by inhibition of carbonated apatite dissolution in vitro. J Biomed Mater Res A 2008;85:993-1000.
32. Xia Z, Dunford J, Lawson MA, Triffitt JT, Barnett BL, Ebetino EB, Russell RGG. Predicting the clinical potencies of bisphosphonates: Divergence of hydroxyapatite and farnesyl diphosphate synthase binding affinities. Calcif Tissue Int 2007;80:S155.
33. Follet H, Li J, Phipps RJ, Hui S, Condon K, Burr DB. Risedronate and alendronate suppress osteocyte apoptosis following cyclic fatigue loading. Bone 2007;40:1172-1177.
34. Reid IR, Miller P, Lyles K, Fraser W, Brown JP, Saidi Y, Mesenbrink P, Su G, Pak J, Zelenakas K, Luchi M, Richardson P, Hosking D. Comparison of a single infusion of zoledronic acid with risedronate for Paget's disease. N Engl J Med 2005;353:898-908.